Adicet Bio, Inc.
Adicet Bio, Inc. (Nasdaq Capital Market: ACET) is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's website is www.adicetbio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Adicet Bio, Inc. does
In the company’s own words
Adicet Bio, Inc. (Nasdaq Capital Market: ACET) is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's website is www.adicetbio.com.
The company's core approach centers on engineering "off-the-shelf" gamma delta T cells derived from peripheral blood cells of unrelated donors, allowing rapid and cost-efficient product candidate generation. This allogeneic manufacturing process enables products to be stored and administered on demand without inducing graft-versus-host immune responses, contrasting with autologous alpha beta T cell therapies that require individualized manufacturing for each patient.
Adicet's lead product candidate, prulacabtagene leucel (prula-cel, formerly ADI-001), is a first-in-class allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20, currently in Phase 1 clinical development across multiple autoimmune indications including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, antineutrophil cytoplasmic autoantibody-associated vasculitis, idiopathic inflammatory myopathy, stiff person syndrome, and rheumatoid arthritis. The FDA granted Fast Track Designation for prula-cel in lupus nephritis and systemic lupus erythematosus with extrarenal involvement, as well as systemic sclerosis.
The company is also advancing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen for metastatic castration-resistant prostate cancer treatment. ADI-212 integrates membrane-tethered IL-12 armoring and CRISPR/Cas9-mediated disruption of the mediator complex to enhance potency in solid tumors.
Adicet maintains strategic collaborations with Regeneron Pharmaceuticals for antigen binding domain development, CRISPR Therapeutics for gene-editing technology, Twist Bioscience for antibody discovery, and the City of Hope for licensing arrangements. The company's intellectual property portfolio includes multiple granted patents and pending applications covering gamma delta T cell expansion platforms, manufacturing processes, and specific product candidates, with patent protection extending through the 2030s and 2040s.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1720580
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Adicet Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Adicet Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Adicet Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Adicet Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Adicet Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”